acid-phosphatase and Prostatitis

The serum levels of gamma-Seminoprotein (gamma-Sm) were determined by enzyme immunoassay in 77 patients with prostatic cancer (30 untreated and 47 treated), 44 patients with benign prostatic hypertrophy and 12 patients with prostatitis. Serum levels of gamma-Sm in each disease were as follows; untreated prostatic cancer 23.2 +/- 18.3 ng/ml (positive rate 93%), treated prostatic cancer 4.7 +/- 8.3 (positive rate 25.5%), benign prostatic hypertrophy 3.6 +/- 3.3 (positive rate 23.7%), prostatitis 2.0 +/- 2.0 (positive rate 7.7%). Serum gamma-Sm levels in prostatic cancer were higher in advanced stage but relatively low in poorly differentiated adenocarcinoma. We consider that the level of serum gamma-Sm is a useful tumor marker as well as prostatic acid phosphatase (PAP) in diagnosis and follow-up of the patients with prostatic cancer.

Topics: Acid Phosphatase; Adenocarcinoma; Biomarkers, Tumor; Blood Proteins; Humans; Immunoenzyme Techniques; Japan; Male; Multicenter Studies as Topic; Neoplasm Staging; Predictive Value of Tests; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatic Secretory Proteins; Prostatitis; Seminal Plasma Proteins

Topics: Acid Phosphatase; Adult; Autopsy; Clinical Trials as Topic; Creatine Kinase; Fructose; Humans; Infertility, Male; L-Lactate Dehydrogenase; Male; Prostate; Prostatitis; Semen; Seminal Vesicles; Spermatozoa; Testis; Vas Deferens; Zinc

A potential etiology of chronic prostatitis/chronic pelvic pain syndrome is autoimmunity. We determined whether T cells from men with chronic prostatitis/chronic pelvic pain syndrome would recognize peptides derived from the normal self-prostatic proteins prostate specific antigen and prostatic acid phosphatase.. CD4 T cells purified from peripheral blood of 31 patients with chronic prostatitis/chronic pelvic pain syndrome and from the buffy coat preparation of 27 normal male blood donors were stimulated in vitro with a panel of immunogenic peptides from prostate specific antigen and prostatic acid phosphatase, and assayed for reactivity with the peptides by interferon-gamma enzyme-linked immunosorbent spot assay. Intermediate resolution HLA typing was done by polymerase chain reaction. Peptides were also tested by binding assay against different class II alleles.. Peptide PAP(173-192) was recognized more frequently by CD4 T cells from patients with chronic prostatitis/chronic pelvic pain syndrome than from healthy donors. The recognition of prostate specific antigen peptides was not statistically different when comparing cases to normal male blood donors individually. Peptide reactivity was more common in patients than in normal male blood donors for any prostate specific antigen peptide or any tested peptide. All peptides showed high promiscuity on binding assays. There was no association of cases with any specific HLA class II phenotype at intermediate resolution.. CD4 T cells from patients with chronic prostatitis/chronic pelvic pain syndrome have a higher rate of recognizing the self-prostatic proteins prostatic acid phosphatase and prostate specific antigen compared to those from normal male blood donors. Data provide further evidence to support the role of autoimmunity in some men with chronic prostatitis/chronic pelvic pain syndrome.

Topics: Acid Phosphatase; Adult; Aged; CD4-Positive T-Lymphocytes; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatitis; Protein Tyrosine Phosphatases

The crucial role of CD4 T-cells in anti-tumor immune response is widely recognized, yet the identification of HLA class II-restricted epitopes derived from tumor antigens has lagged behind compared to class I epitopes. This is particularly true for prostate cancer. Based on the hypothesis that successful cancer immunotherapy will likely resemble autoimmunity, we searched for the CD4 T-cell epitopes derived from prostatic proteins that are restricted by human leukocyte antigen (HLA)-DRB1*1501, an allele associated with granulomatous prostatitis (GP), a disease that may have an autoimmune etiology. One of the antigens implicated in the development of autoimmunity in the prostate is prostatic acid phosphatase (PAP), which is also considered a promising target for prostate cancer immunotherapy.. We immunized transgenic (tg) mice engineered to express HLA-DRB1*1501 with human PAP. A library of overlapping 20-mer peptides spanning the entire human PAP sequence was screened in vitro for T-cell recognition by proliferative and interferon (IFN)-gamma enzyme-linked immunosorbent spot (ELISPOT) assays.. We identified two 20-mer peptides, PAP (133-152), and PAP (173-192), that were immunogenic and naturally processed from whole PAP in HLA-DRB1*1501 tg mice. These peptides were also capable of stimulating CD4 T lymphocytes from HLA-DRB1*1501-positive patients with GP and normal donors.. These peptides can be used for the design of a new generation of peptide-based vaccines against prostate cancer. The study can also be helpful in understanding the role of autoimmunity in the development of some forms of chronic prostatitis.

Topics: Acid Phosphatase; Alleles; Amino Acid Sequence; Animals; Cancer Vaccines; CD4-Positive T-Lymphocytes; Cells, Cultured; Epitopes; HLA-DR Antigens; HLA-DR2 Antigen; HLA-DRB1 Chains; Humans; Male; Mice; Mice, Transgenic; Molecular Sequence Data; Peptides; Prostatic Neoplasms; Prostatitis; Protein Tyrosine Phosphatases

Acute and chronic infectious prostatitis are the best understood of the prostate syndromes, but they are the least frequent. In contrast, although chronic non-infectious prostatitis is the most frequent syndrome, its cause has proved elusive despite years of investigation. In the present study, we analyzed a group of patients with infectious and non-infectious chronic prostatitis in order to search for the presence of a possible autoimmune response to prostate antigens. We demonstrated the presence of lymphocytes able to proliferate in response to known human prostate antigens such as PSA and PAP only in a group of patients with non-infectious chronic prostatitis. We observed that, as in other autoimmune diseases, a proliferative response against two or more autoantigens was a common feature. Moreover, when INFgamma and IL-10 levels were measured in culture supernatants, significantly elevated levels of INFgamma were detected only in samples from patients with positive proliferative response to prostate antigens. Interestingly, only these patients showed significantly elevated levels of inflammatory cytokines (IL-1 and TNF-alpha) in seminal plasma, arguing for a local inflammation of non-infectious cause. Our results show that INFgamma-secreting lymphocytes specific to prostate antigens are in fact detected in 34% of the patients with chronic non-infectious prostatitis. We speculate that these cells could be involved in the inflammatory process taking place in the prostate gland and therefore could alter its biological function.

Topics: Acid Phosphatase; Adult; Antibody Formation; Antigen Presentation; Antigens; Autoimmunity; Cell Proliferation; Chronic Disease; Extracellular Fluid; Humans; Immunity, Cellular; Interferon-gamma; Interleukin-1; Interleukin-10; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocytes; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatitis; Protein Tyrosine Phosphatases; Semen; Tumor Necrosis Factor-alpha

The treatment for chronic nonbacterial prostatitis (NBP) has not been established. Cernitin pollen-extract (CN-009) is reported to have therapeutic effects for NBP. The effects and mechanisms of CN-009 were investigated.. Ten-month-old rats were used with administration of estradiol after castration, which were similar to human NBP histologically. Since CN-009 consists of T-60 and GBX, these drugs were administered, respectively. The prostate was evaluated histopathologically including glandular damage (epithelial score), stromal ratio and immunohistochemical assays for epithelial function (PAP), stromal evaluation (Vimentin), cell proliferation (PCNA) and apoptosis (deoxyuridine triphosphate biotin nick end-labeling (TUNEL)).. Controls revealed severe acinar gland atrophy and stromal proliferation. CN-009 showed diminished these damages. Epithelial score was better (P < 0.01) and PAP positive materials were more abundant in CN-009 and GBX than in Controls. The stromal ratio was lower in CN-009 (P < 0.01) and T-60 (P < 0.05). There was no difference for PCNA positive cells in the epithelium and stroma, and TUNEL positive cells in epithelium. While, the number of TUNEL positive cells in the stroma of CN-009 and T-60 increased (P < 0.01).. These findings suggest that CN-009 protects acinar epithelial cells mainly by GBX and also inhibits stromal proliferation in association with enhanced apoptosis mainly by T-60.

Topics: Acid Phosphatase; Animals; Apoptosis; Disease Models, Animal; Epithelial Cells; Estradiol; Immunohistochemistry; In Situ Nick-End Labeling; Male; Orchiectomy; Phytotherapy; Plant Extracts; Pollen; Proliferating Cell Nuclear Antigen; Prostatitis; Rats; Rats, Wistar; Secale; Statistics, Nonparametric; Stromal Cells; Vimentin

Inflammation is a common finding in benign prostatic hyperplasia (BPH) and may be classified as acute, chronic active or chronic inactive prostatitis. The aim of the present study was to localise the different types of inflammatory cells in prostatic lesions to determine the sequence of events in the cellular reaction. We have carried out immunohistological characterisation of the inflammatory cells, using CD45RO and CD3 antibodies to detect T-lymphocytes, CD20 antibodies to detect B-lymphocytes, CD68 to detect macrophages, kappa and lambda immunoglobulin light chains, and antibodies against prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP). Macrophages accumulated in the lumen and glandular epithelial layers of damaged prostatic glands and were found in the periglandular cuff of inflammatory cells in acute and chronic active prostatitis. Lymphocytes also accumulated in large numbers in the glandular epithelial layers and around the glands, indicating an association with macrophages. B-lymphocytes were scanty, if at all present, in acute and chronic active prostatitis, but were prominent within well-organised follicle centres in chronic active prostatitis. Cells positive for light chains were few and scattered in prostatic tissue. PSA and PSAP activity was lost in recently damaged prostatic glandular epithelium and reappeared only in regenerating secretory epithelium, indicating leakage as a result of damage. We suggest that the initial response to prostatic injury is cellular, and probably related to leakage into the periglandular tissues of PSA, PSAP and other antigenic molecules normally present in prostatic secretion. Macrophages respond, followed by recruitment of T-lymphocytes which participate in the inflammatory response and accumulate around the damaged glands. B-cell activity appears to be a late event.

Topics: Acid Phosphatase; Acute Disease; Antigens, CD; B-Lymphocytes; Chronic Disease; Humans; Immunoenzyme Techniques; Immunoglobulin Isotypes; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Macrophages; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatitis; T-Lymphocytes

Prostatic acid phosphatase (PAP) is uniquely expressed in prostatic tissue and prostate cancer. In this study, the immunogenicity of PAP was investigated in a male rat model. We show that immunization with recombinant rat or human PAP in CFA leads to a significant Ab response, but does not generate CTL or result in autoimmune prostatitis. In contrast, immunization with recombinant vaccinia expressing human PAP, but not rat PAP, generates a CTL response and tissue-specific prostatitis in the absence of detectable PAP-specific Abs. These findings suggest that a cellular immune response to PAP, rather than Abs, mediates destructive autoimmune prostatitis. Thus, xenogeneic forms of PAP are a new tool for the induction of prostate-specific immunity and may prove useful for the immunotherapy of prostate cancer.

Topics: Acid Phosphatase; Animals; Autoimmune Diseases; Humans; Immunotherapy, Active; Injections, Intravenous; Injections, Subcutaneous; Male; Organ Specificity; Prostate; Prostatic Neoplasms; Prostatitis; Rats; Rats, Inbred Strains; Tumor Cells, Cultured; Vaccines, Synthetic; Vaccinia virus

The present status of tumor markers in prostate cancer, especially prostate-specific antigen (PSA), for diagnosis and follow-up of prostate cancer patients was reviewed. Due to tissue-specific protein of PSA as well as PAP, serum PSA levels may increase in patients with benign hyperplasia (BPH) which is the disease necessary for differential diagnosis from prostate cancer. Therefore, it has been believed to be difficult to differentiate early stages of prostate cancer from BPH using only PSA determination. However, with the use of recently developed assay systems, the detection of PSA-protease inhibitor complex, or PSA-density, the detection of early stages of prostate cancer may be possible. In following up prostate cancer patients, serially determined PSA is one of the best tools to evaluate treatment response and early detection of disease progression.

Topics: Acid Phosphatase; Biomarkers, Tumor; Counterimmunoelectrophoresis; Diagnosis, Differential; Humans; Immunoenzyme Techniques; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatic Secretory Proteins; Prostatitis; Proteins; Radioimmunoassay; Seminal Plasma Proteins

Nonbacterial prostatitis is often difficult to differentiate from other prostatic complaints and remains a vaguely characterized syndrome. Prostatic fluid inflammatory cells and elevated immunoglobulins raise the suspicion that this syndrome is caused by some undetected infection. Prostatic fluid antibodies against Chlamydia trachomatis, Ureaplasma urealyticum, staphylococcus, Staphylococcus faecalis, Bacteroides fragilis and Clostridium perfringens were measured in men with nonbacterial and bacterial prostatitis, and men without urinary symptoms by an enzyme-linked immunosorbent assay. Prostate specific antigen and prostatic acid phosphatase were measured in the prostatic fluid as indirect measures of secretory activity. Of 44 men with nonbacterial prostatitis 9 (20%) had detectable prostatic fluid antichlamydial antibody titers, compared with 3 of 25 control men (12%) and 2 of 13 (15%) with bacterial prostatitis--no evidence for a higher prevalence of prostatic fluid antichlamydial antibody in men with nonbacterial prostatitis. Prostatic antibodies to the other organisms were rarely detected. When compared with unaffected men the low levels of prostate specific antigen and prostatic acid phosphatase, and more alkaline prostatic fluid in men with bacterial and nonbacterial prostatitis suggest that secretory dysfunction accompanies the inflammation. These data show that none of the organisms studied caused the majority of the cases of nonbacterial prostatitis and that either an agent as yet unidentified or multiple agents may be involved in the etiology of nonbacterial prostatitis.

Topics: Acid Phosphatase; Antibodies, Bacterial; Bacteroides fragilis; Chlamydia trachomatis; Clostridium perfringens; Humans; Immunoglobulins; Male; Prostate; Prostate-Specific Antigen; Prostatitis; Staphylococcus; Ureaplasma urealyticum

We studied 78 men with suspicion of prostatic carcinoma, who underwent transrectal aspiration biopsy, diagnosing 46 adenocarcinoma, 13 chronic prostatitis and 19 benign prostatic hyperplasia. Moreover, we determined prostatic acid phosphatase (PAP) by enzyme immunoanalysis, resulting in 9/78 false-positives and 18/78 false-negatives. Also, we carried out a morphometric analysis of the cytologic samples which showed good correlation with the cytologic diagnosis except in the moderately differentiated carcinomas. We found a good correlation between PAP values, cytologic diagnosis and nuclear size as well as the percentage of the binucleolated cells.

Topics: Acid Phosphatase; Adenocarcinoma; Biopsy, Needle; Chronic Disease; False Negative Reactions; False Positive Reactions; Humans; Male; Prospective Studies; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis

Infections of the prostate may occur despite the numerous host defences of the male urogenital tract. It is important to distinguish patients with genuine inflammation of the gland from the larger number of men with symptoms but no signs of an inflammatory response (prostatodynia). To define prostatitis, the degree of the inflammatory reaction must first be determined. Increased numbers of leucocytes in expressed prostatic secrections (EPS) are essential for this diagnosis. Careful lower urinary tract studies may then be used to classify the patients into two major groups of bacterial and nonbacterial prostatitis. Chronic bacterial prostatitis is primarily due to Escherichia coli. Gram-positive prostatitis is debatable. In chronic bacterial prostatitis, secretory dysfunction is common. The increased alkalinity of the pH of expressed prostatic secretions is one of the reasons for poor results of antibiotic therapy. Uncommon microorganisms, such as Chlamydia trachomatis and Ureaplasma urealyticum may be involved in some cases of the "nonbacterial" form. Routine culture for these microorganisms is not recommended.

Topics: Acid Phosphatase; Acute Disease; Biopsy; Chronic Disease; Diagnosis, Differential; Granulocytes; Humans; Hydrogen-Ion Concentration; Immunoglobulins; L-Lactate Dehydrogenase; Leukocyte Count; Male; Prostate; Prostatitis; Specific Gravity

Granulomatous prostatitis may result from tuberculosis and fungal infection and has been described following prostatic surgery. In most cases, however, the aetiology is unknown, although it may be due to a reaction to extravasated or altered prostatic secretions. We have investigated cells (macrophages, lymphocytes), serum proteins (fibrinogen, alpha 1-antitrypsin) and prostatic epithelial products (prostatic-specific antigen and prostatic acid phosphatase) in diffuse granulomatous prostatitis (3 cases), focal periacinar prostatic granulomas (9) and focal prostatic infarcts (5), using an immunohistological technique. T-lymphocytes and macrophages are present in diffuse and focal granulomatous prostatitis, but few B-lymphocytes occur. Fibrinogen-related antigen is absent from granulomas, but a small amount is present within infarcts, whereas plentiful alpha 1-antitrypsin was detected both in granulomas and infarcts. Significant reduction in prostatic-specific antigen and acid phosphatase reactivity occurs in granulomatous prostatitis. This suggests that cytokines derived from activated macrophages and T-lymphocytes may be exerting a cell regulatory effect and altering cell secretions, as well as causing destruction of the prostatic epithelium.

Topics: Acid Phosphatase; Aged; Aged, 80 and over; alpha 1-Antitrypsin; Antigens, Neoplasm; Fibrinogen; Giant Cells; Granuloma; Humans; Immunohistochemistry; Lymphocytes; Macrophages; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatitis

We used the method of Rudolph et al. (Clin Chem 1988; 34:2031-8) to find information in the data from correlated determinations of acid phosphatase (PAP, EC 3.1.3.2; DuPont aca) and prostate-specific antigen (PSA, Hybritech). We described there how we assign medical decision limits for two or more correlated variables and convert the database to a binary coded message, allowing separation of a selected disease class with minimum error. The decision point, analogous to a percentile upper limit on the ordered values of each variable in the reference group, satisfies the maximum entropy constraints of reference, producing a minimum entropy for the binary coded patient database. We found maximum entropy decision points at PAP = 0.75 U/L and PSA = 22.8 micrograms/L. Patients with PSA values exceeding 22.8 micrograms/L had no benign prostatic disease except for five patients with benign prostate hyperplasia (BPH) with adjacent colon carcinoma (95.3), BPH with infarction (27.6), BPH (23.4) 28.1), or acute prostatitis (34.6). We consider PSA exceeding 22.8 micrograms/L as indicative of carcinoma of the prostate, stage C or D, in the absence of disconfirming evidence. Another decision value for PSA is 11.3 micrograms/L. This bounds the region between 11.3 and 22.8 micrograms/L, where the frequency of BPH is 1.5 times that for adenocarcinoma. At PSA less than 11.3 micrograms/L there is a high frequency of BPH. PSA concentration is not correlated with prostatic size (mass) or with prostatitis. A metastatic carcinoma is as likely to be nonprostatic as prostatic when the PSA concentration is less than 11.3 micrograms/L.

Topics: Acid Phosphatase; Adenocarcinoma; Antigens, Neoplasm; Biomarkers, Tumor; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Risk Factors; Statistics as Topic

Blood samples from 500 patients with clinical prostatic symptoms were radioimmunoassayed with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) kits. On the basis of histological data, directed by PSA results and other investigations, 200 prostatic cancers (adenocarcinomas), 276 benign prostatic hypertrophy (BPH), 16 cases of prostatitis, 5 cancers of the bladder, and 3 prostatodynias were diagnosed. All of the serum samples from prostatic cancer patients showed elevated PSA levels at diagnosis, whereas about 70% of these showed normal PAP values. The sensitivity of the PSA assay is 100% when 2.5 ng/ml is taken as the upper limit of normal. However, the specificity and the positive predictive value are better at 10 ng/ml: 99 and 79%, respectively. High PSA values alerted the clinician when diagnosing a cancer without symptoms on rectal or ultrasonographic examination (3%). In BPH, when the PSA level is between 2.5 and 10 ng/ml, a PSA control must be performed within 2 months. If PSA increases above 10 ng/ml, the risk of cancer has to be considered. In the follow-up, PSA is a better marker than PAP to detect disease progression and seems to constitute an evolutive tumor mass index. PSA is the most sensitive, the earliest, and the most prognostically reliable marker for diagnosis and follow-up of prostate cancer patients.

Topics: Acid Phosphatase; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Radioimmunoassay

Prostatic specific antigen (PA) level was determined with a Wako test kit (Japan) for prostatic cancer and others. The incidence of abnormal values of PA in untreated prostatic cancer, was 50, 50, 80, and 100% for stage A1, C (pN0, NX), D1 and D2 cancers, respectively. Grade was not related to the level of PA. Prostatic hypertrophy, prostatitis and urinary stone showed a false positive rate of 52, 18 and 0%, respectively. The level of PA was not correlated to those of prostatic acid phosphatase (RIA). In 31% of the cases, the elevated PA decreased 4 weeks after start of endocrine treatment. Elevated PA in low grade cancer was not normalized as much as that in high and moderate grade cancers. The positive rate of PA in the serum of reactivated patients was significantly higher than that of the patients with cancer under good control by endocrine treatment.

Topics: Acid Phosphatase; Antigens, Neoplasm; False Positive Reactions; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Urinary Calculi

Prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) have been evaluated in patients with prostate cancer, benign prostatic hypertrophy (BPH), and prostatitis. PSA has proved to be diagnostically more sensitive than PAP for the detection of prostate cancer: 95.0 per cent vs 60.0 per cent for 40 newly diagnosed cancer cases, and 97.1 per cent vs 65.7 per cent for 35 relapsed cases. This also holds true for those patients with early-stage disease: 71.4 per cent vs 0 per cent for 7 Stage A1 cases. The specificities of PSA and PAP are comparable, 96.8 per cent vs 98.9 per cent, respectively. PSA is also more sensitive for monitoring therapy, since it usually rises before PAP and always precedes clinical signs of relapse. Although PSA may be elevated more frequently than PAP in some patients with BPH and prostatitis, it is postulated that these patients with elevated serum PSA and normal serum PAP may fall into a high-risk sub-population which may have early prostate cancer or precancerous conditions not easily detectable by current clinical and diagnostic techniques. Our data suggest PSA is a sensitive useful tumor marker for the diagnosis and management of prostate cancer. In addition, PAP, in combination with PSA, may serve as a useful adjunct for differential diagnosis and confirmation of advanced stage prostate cancer.

Topics: Acid Phosphatase; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis

The clinical usefulness of PAP and PA as a tumor marker for the prostate cancer were discussed. The materials for this study were 1385 cases which contained 158 cases with prostatic carcinoma. The positive rate of serum PAP and PA were 77.7% and 94.1% in untreated prostatic carcinoma and 15.1% and 70.0% in benign prostatic hypertrophy using 3.0 ng/ml as an upper limit of normal controls of serum PAP and PA. The cut off level in serum PA should be discussed more. PA was not superior to PAP as a tumor marker in the series, but our results have suggested the simultaneous assay of serum PAP and PA is valuable in detection and following-up of prostate cancer.

Topics: Acid Phosphatase; Adult; Aged; Antigens, Neoplasm; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis

Prostatic acid phosphatase was determined with Merck-Kanto's test kit on the cases of prostatic cancer experienced at our University Hospital from August in 1983 to February in 1985. Untreated cases were 4 stage A cases, 1 stage B case, 3 stage C cases, 3 stage D1 cases and 12 stage D2 cases. Nine cases were determined before and after hormonal treatment. From 67 controlled cases and 19 recurrent cases, 144 and 56 samples were selected, respectively. This method showed good reproducibility and even the serum stored at -80 degrees C after separation could be used for determination by addition of tartrate just before the measurement. The occurrence of abnormal values in untreated prostatic cancer cases, was 0% for stage A, 1 case for stage B, 33% for stage C and D1 and 75% for stage D2. Hormonal treatment decreased the high values of 5 cases and 1 case returned to normal. Compared to the recurrent cases, controlled cases showed a significantly larger ratio of negative, and it suggests that the test is useful for follow-up. Prostatic hypertrophy showed the increase of the value in 6% of the cases. Both prostatitis and urinary tract stone cases remained in the normal range.

Topics: Acid Phosphatase; Humans; Immunoenzyme Techniques; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Radioimmunoassay; Tartrates

The heterogeneity of gamma-glutamyltranspeptidase (GGT) in seminal plasma has been studied using Con A-chromatography. This parameter was then related to the fructose concentration, the acid phosphatase activity, ejaculate volume, sperm density and the number of bacteria per ml. Multivariate regression analysis and stepwise elimination of the least fitting factors, revealed that Con A-binding correlated with the number of bacteria per ml of semen and the acid phosphatase activity with 49% of the variance of GGT-binding being explained by these parameters. This result suggests that glycosylation of seminal GGT is altered by accessory gland infection. Neuraminidase digestion suggests that the pattern of Con A-binding of seminal GGT depends only partly on its sialic acid content.

Topics: Acid Phosphatase; Carbohydrate Metabolism; Chromatography, Affinity; Concanavalin A; gamma-Glutamyltransferase; Genital Diseases, Male; Humans; Infections; Male; Neuraminidase; Prostatitis; Semen

The levels of prostatic serum acid phosphatase (PSAP) were determined by radioimmunoassay using RIA-Quant PAP test kit on 14 normal females, 56 normal males, 25 patients with prostatitis, 74 patients with benign prostate hypertrophy, 129 patients with prostatic cancer, 50 patients with nonprostatic malignancies, and 16 post radical cystectomized males, making 364 cases in all. To diagnose prostatic cancer, a PSAP level of over 3.0 ng/ml was determined positive for differential diagnosis of prostatitis, benign prostate hypertrophy, and prostatic cancer. According to this criterium, the positive rate for each type of disease was: 0% for prostatitis, 5.4% for benign prostate hypertrophy, 80.6% for untreated prostatic cancer, and 2% for nonprostatic malignancies. In benign prostate hypertrophy, the cases with urethral catheters showed a tendency of high PSAP level, but no significant difference was observed. PSAP positive rates of untreated prostatic cancer by stage are 0% for Stage A, 57.1% for Stage B, 85.7% for Stage C, 100% for Stage D1, and 94.1% for Stage D2 cases at a high stage showing high positive rates. However, there seems to be a limit for the diagnosis of early prostatic cancer. As for the relationship between the grade of untreated prostatic cancer and PSAP, well differentiated tumors showed higher levels of PSAP in the study with cases of the same stage. However, with all the cases, less well differentiated tumors showed higher levels of PSAP. As a tumor marker for prostatic cancer in the observation of treatment response, the PSAP level of over 2.0 ng/ml was determined positive. The relationship between the judgement of treatment response and PSAP was: Objective stable for its increase or decrease within the normal range; progressive disease for its elevation from normal to positive level, or increase or decrease of PSAP level within the positive range; Objective partial regression or objective stable for normalization from positive level. The PSAP level in the internal iliac vein of the patients with prostatic cancer tended to be higher than that in the femoral vein or antecubital vein.

Topics: Acid Phosphatase; Adolescent; Adult; Aged; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Radioimmunoassay

A prospective study comparing a new radioimmunologic and a classical enzymatic assay for prostatic acid phosphatase was done to evaluate their respective roles in patients with prostatic diseases. We studied 50 patients with cancer of the prostate, 101 with benign prostatic hypertrophy and 17 with prostatitis as well as patients with nonprostatic malignancy, and various hematological and bone diseases. The results showed a low incidence of elevated values in patients with early cancer of the prostate and a high incidence of false positive values with the radioimmunoassay in patients with benign prostatic diseases, especially prostatitis. These data suggest that tests for serum prostatic acid phosphatase levels remain disappointing in the assessment of prostatic disease regardless of the technique used.

Topics: Acid Phosphatase; Aged; False Positive Reactions; Humans; Male; Prospective Studies; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Radioimmunoassay

Two radioimmunoassay procedures (RIA-1 and RIA-2) were evaluated for the quantitation of prostatic acid phosphatase in serum and compared with the enzymatic method and counter immunoelectrophoresis method for their specificity and sensitivity. Sera from 168 patients were analyzed and these included: normals, 27; untreated prostatic cancer patients Stage A, 2; Stage C, 3; Stage D, 17; cancer of prostate treated with different modalities, 42; sarcoma of prostate, 1; prostatitis, 3; nonprostatic carcinoma, 17; and benign prostatic hyperplasia (BPH), 56. RIA-1 procedure appeared more sensitive (82% sensitivity) and specific (94.5% specificity) than the RIA-2 procedure (68% sensitivity and 91.8% specificity), but the differences were not statistically significant. The enzymatic method was found to be least sensitive (63.6% sensitivity) but also the most specific (100% specificity). Only 69 of the specimens were analyzed by counter immunoelectrophoresis, which showed sensitivity of 87% and specificity of 51.4%. False positives were observed more often in patients with nonprostatic cancer and BPH. The variations in diagnostic specificity of immunologic assays suggest the need of characterization of each antibody specificity.

Topics: Acid Phosphatase; Adult; Aged; Antibody Specificity; Counterimmunoelectrophoresis; Evaluation Studies as Topic; False Positive Reactions; Humans; Immunoelectrophoresis; Immunoenzyme Techniques; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Radioimmunoassay; Sarcoma

Topics: Acid Phosphatase; Clinical Enzyme Tests; Humans; Male; Massage; Palpation; Prostatic Diseases; Prostatic Hyperplasia; Prostatitis

The diagnosis of male adnexitis is difficult and the influence of this condition on fertility is still a matter of debate. With the intention to define diagnostic criteria a comprehensive study of biochemical and morphological features of semen, plus culture for microorganisms, was performed in patients who were assessed for infertility during a four year period. The following parameters were considered of diagnostic value: a) history of urogenital infection and/or abnormal rectal palpation. b) significant alterations in the expressed prostatic fluid and/or urinary sediment after prostatic massage. c) 1. Uniform growth of more than 10(3) pathogenic bacteria, or more than 10(4) non-pathogenic bacteria per ml, in culture of diluted seminal plasma. c) 2. Presence of more than 10(6) (peroxidase positive) leucocytes per ml of ejaculate. c) 3. Signs of disturbed secretory function of the prostate or seminal vesicles. The diagnosis of infection is accepted if either of the following combinations if found: a + b, a + c (1 or 2 or 3), b + c (1 or 2 or 3), c1 + c2, c1 + c3, c2 + c3.

Topics: Acid Phosphatase; Bacterial Infections; Fructose; Genital Diseases, Male; Humans; Infertility, Male; Leukocytes; Male; Prostate; Prostatitis; Semen; Seminal Vesicles

A high incidence of spontaneous, non-acute, age-dependent prostatitis was observed in the lateral prostate of Copenhagen rats and Wistar rats. The lumen of infected acini was filled with polymorphonuclear leucocytes, shed epithelial cells and cell residues. Epithelial cells lining such acini showed degenerative changes. Lymphocytes and macrophages were seen in the stroma. A histochemically observed increase in acid phosphatase and beta-glucuronidase activity in affected epithelial cells may indicate an increased lysosomal activity. Some bacteriological cultures of infected lateral prostates were positive for Proteus vulgaris and diphtheroids. It is suggested that this spontaneous rat prostatitis may be a useful model for the study of the pathogenesis and treatment of human non-acute prostatitis.

Topics: Acid Phosphatase; Age Factors; Alkaline Phosphatase; Animals; Bacteria; Disease Models, Animal; Epithelium; Esterases; Glucuronidase; Leucyl Aminopeptidase; Male; Prostate; Prostatitis; Rats

Critic acid was determined in the ejaculate in 100 cases. No significant correlations between citric acid values and other parameters of the spermiogram were found. In accordance with literary data we found low citric acid values in prostatitis and hypogonadism.

Topics: Acid Phosphatase; Citrates; Fructose; Humans; Hydrogen-Ion Concentration; Hypogonadism; Infertility, Male; Male; Prostatitis; Semen; Sperm Motility

Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Biopsy; Biopsy, Needle; Bone Marrow Examination; Castration; Cryosurgery; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prostatectomy; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Radiography, Thoracic; Radionuclide Imaging; Steroids

Topics: Acid Phosphatase; Aged; Biopsy; Carcinoma; Diagnosis, Differential; Granuloma; Humans; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis

Topics: Acid Phosphatase; Age Factors; Aged; Fibroma; Humans; Hyperplasia; Intubation, Intratracheal; Male; Methods; Middle Aged; Prostate; Prostatectomy; Prostatic Neoplasms; Prostatitis; Pulmonary Heart Disease; Tartrates; Urinary Catheterization; Urinary Diversion

Topics: Acid Phosphatase; Adenocarcinoma; Aged; Biopsy; Carcinoma; Cystoscopy; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Punctures

Topics: Acid Phosphatase; Blood Chemical Analysis; Clinical Enzyme Tests; Humans; Male; Metabolism; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Protein Tyrosine Phosphatases; Urology

Topics: Acid Phosphatase; Body Fluids; Chronic Disease; Disease; Humans; Male; Peptide Hydrolases; Prostate; Prostatic Diseases; Prostatitis